...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

At the Zenith  2022 AGM DM also specifically stated alot was going on behind the scenes  from both companies) and for the first time he stated 1 or both could have deal s at some point  This unexpected quiet period from RVX from Sept 22 to now is the first time i can remember not 1 NR over a 5  month period. I do also agree Zenith might get a larger partnership or cvr deal this year as well.  Lots of clinical data and positives on the Zenith for Pharma's to stay on the sidelines and they are flush with billions of dollars in cash .

Share
New Message
Please login to post a reply